Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 1.62 USD 0.62% Market Closed
Market Cap: 431.1m USD

Autolus Therapeutics PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Autolus Therapeutics PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Operating Activities
-$254.2m
CAGR 3-Years
-33%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Operating Activities
-$239.7m
CAGR 3-Years
-54%
CAGR 5-Years
-108%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
£26.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
£67.2m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
7%
Oxford BioMedica PLC
LSE:OXB
Cash from Operating Activities
-£7.8m
CAGR 3-Years
28%
CAGR 5-Years
-6%
CAGR 10-Years
3%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
431.1m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
10.02 USD
Undervaluation 84%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-254.2m USD

Based on the financial report for Sep 30, 2025, Autolus Therapeutics PLC's Cash from Operating Activities amounts to -254.2m USD.

What is Autolus Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-16%

Over the last year, the Cash from Operating Activities growth was -32%. The average annual Cash from Operating Activities growth rates for Autolus Therapeutics PLC have been -33% over the past three years , -16% over the past five years .

Back to Top